Bicyclic dione racetam analog

Plain-language summaryIntrigue 28 / 100

Dimiracetam is a bicyclic dione racetam analog. Limited published research; used in academic settings to study racetam structure-activity relationships. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Structurally distinct NMDA-leaning racetam with modest Phase 2 CIPN signal and stalled development

Look, dimiracetam occupies a peculiar middle zone in the racetam family tree. It’s not the piracetam everyone already knows, and it’s not some purely preclinical compound riding a single lab’s claims. Sigma-Tau ran actual Phase 2 trials in chemotherapy-induced peripheral neuropathy, which puts it ahead of most of its structural cousins on the evidence ladder. But “Phase 2 with modest results” and a program that never cleared Phase 3 for commercial and design reasons isnt exactly a ringing endorsement, either.

The structural angle is worth taking seriously. The 1,4-diazabicyclo[3.3.0]octane-2,5-dione scaffold is a fused bicyclic system with two carbonyls per ring, which is a real departure from the flat pyrrolidone cores of piracetam and its descendants. More importantly, the mechanism appears to diverge meaningfully: where standard racetams act primarily through AMPA receptor potentiation, dimiracetam shows glutamatergic effects with an NMDA-related character. Thats a genuine mechanistic distinction within the class, and its probably the reason the compound showed any signal at all in a neuropathic pain indication that AMPA potentiators have no obvious reason to address.

Here’s the thing though: NMDA modulation for neuropathic pain isnt novel pharmacology at the population level. Ketamine, memantine, and a well-trodden literature on NMDA channel blockers predate dimiracetam by decades. The compound may be engaging those pathways through a structurally unusual route, but it hasnt demonstrated that its particular binding profile offers anything decisively superior to existing agents in that space. Phase 2 data showed reduction in pain measures, but the effect sizes were described as modest and the program stalled. Thats a compound that failed to prove itself, not one that was proven wrong, but the distinction matters less at the bench than it sounds.

For investigators, there’s residual probe value specifically in comparing NMDA-adjacent mechanisms across structurally divergent scaffolds, or in studying CIPN pathophysiology at a mechanistic level where you want a compound with actual Phase 2 safety data. That’s a real but narrow use case. Limited research-grade sourcing is a practical constraint that compounds the thin replication record; you cant lean heavily on prior literature when designing studies because there simply isnt much of it outside the Sigma-Tau-affiliated work.

We think dimiracetam is a legitimate but low-priority research object. Investigators already running SAR programs on bicyclic heterocycles or mechanistic CIPN work have reason to look at it. Everyone else should probably let the Phase 3 story play out before committing bench time.

Novelty: 42
Mechanism promise: 45
In-category differentiation: 40
Evidence quality: 40
Translational signal: 38
Research bench value: 38

Rationale Dimiracetam earns mild interest for its genuinely unusual bicyclic scaffold and NMDA-adjacent mechanism within a class almost exclusively defined by AMPA potentiation, plus real Phase 2 clinical data in CIPN; however, modest effect sizes, a program that never cleared Phase 3, limited research-grade availability, and near-zero replication outside Sigma-Tau keep all six axes clustered in the 38-45 band, producing a low-40s overall with no applicable cap.

Bicyclic dione racetam analog

A bicyclic 2,5-pyrrolidinedione developed by Sigma-Tau for chemotherapy-induced peripheral neuropathy.

Abstract

Dimiracetam (1,4-diazabicyclo[3.3.0]octane-2,5-dione; CAS 126716-03-2; molecular formula C7H10N2O2; molecular weight 154.17) is a bicyclic 2,5-pyrrolidinedione developed by Sigma-Tau (now Defiante Farmaceutica) in Italy with development focused on chemotherapy-induced peripheral neuropathy. The compound is structurally distinct from open-chain racetams in featuring a fused bicyclic scaffold with two carbonyls per ring. Mechanism is incompletely characterized but appears to involve modulation of glutamatergic transmission with NMDA-related effects, distinct from the AMPA potentiation typical of racetams. Phase 2 trials in chemotherapy-induced peripheral neuropathy showed modest reduction in neuropathic pain measures; the program advanced toward Phase 3 but encountered commercial and design challenges. The compound is not approved by any regulatory authority. Limited research-grade availability. Pharmacokinetics: short half-life (1 to 2 hours) and high oral bioavailability. Clinical doses in Phase 2 ranged from 200 to 1600 mg per day in divided administrations.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-039Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Bicyclic dione racetam analog

Dimiracetam

Abstract

Read the full monograph